Back
24
Day Range
$39.24
$40.04
52-Week Range
$38.13
$57.82
Volume
1,580,735
50D / 200D Avg
$48.45
/
$47.37
Prev Close
$39.49
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 19.3 | 0.4 |
| P/B | 2.2 | 2.9 |
| ROE % | 11.6 | 3.9 |
| Net Margin % | 20.3 | 3.8 |
| Rev Growth 5Y % | -1.9 | 10.0 |
| D/E | 0.4 | 0.2 |
Analyst Price Target
Hold
$54.33
+36.6%
Low: $50.00
High: $59.00
Forward P/E
15.7
Forward EPS
$2.52
EPS Growth (est.)
+0.0%
Est. Revenue
2.2 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$3.54
$3.51 – $3.59
|
2.8 B | 2 |
| FY2029 |
$3.27
$3.25 – $3.32
|
2.6 B | 2 |
| FY2028 |
$3.02
$2.74 – $3.66
|
2.5 B | 4 |
Key Takeaways
Revenue declined -1.85% annually over 5 years
Earnings grew 408.28% over the past year
ROE of 11.57% — decent returns on equity
Net margin of 20.33% shows strong profitability
Debt/Equity of 0.44 — conservative balance sheet
Generating 453.28M in free cash flow
Growth
Revenue Growth (5Y)
-1.85%
Revenue (1Y)5.65%
Earnings (1Y)408.28%
FCF Growth (3Y)23.61%
Quality
Return on Equity
11.57%
ROIC7.18%
Net Margin20.33%
Op. Margin24.90%
Safety
Debt / Equity
0.44
Current Ratio3.90
Interest Coverage15.65
Valuation
P/E Ratio
19.29
P/B Ratio2.17
EV/EBITDA17.32
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 5.65% | Revenue Growth (3Y) | 3.12% |
| Earnings Growth (1Y) | 408.28% | Earnings Growth (3Y) | 11.57% |
| Revenue Growth (5Y) | -1.85% | Earnings Growth (5Y) | -4.58% |
| Profitability | |||
| Revenue (TTM) | 2.09B | Net Income (TTM) | 424.88M |
| ROE | 11.57% | ROA | 6.75% |
| Gross Margin | 61.79% | Operating Margin | 24.90% |
| Net Margin | 20.33% | Free Cash Flow (TTM) | 453.28M |
| ROIC | 7.18% | FCF Growth (3Y) | 23.61% |
| Safety | |||
| Debt / Equity | 0.44 | Current Ratio | 3.90 |
| Interest Coverage | 15.65 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 19.29 | P/B Ratio | 2.17 |
| P/S Ratio | 3.92 | PEG Ratio | 0.05 |
| EV/EBITDA | 17.32 | Dividend Yield | 0.01% |
| Market Cap | 8.20B | Enterprise Value | 9.01B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.09B | 1.98B | 1.97B | 2.14B | 2.25B |
| Net Income | 424.88M | 83.59M | 341.30M | 423.21M | 512.60M |
| EPS (Diluted) | 2.04 | 0.38 | 1.65 | 2.05 | 2.47 |
| Gross Profit | 1.29B | 967.35M | 1.23B | 1.38B | 1.45B |
| Operating Income | 520.31M | 97.71M | 409.94M | 531.46M | 630.08M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 6.30B | 5.69B | 6.12B | 6.29B | 6.15B |
| Total Liabilities | 2.52B | 2.12B | 2.31B | 2.82B | 3.05B |
| Shareholders' Equity | 3.78B | 3.57B | 3.81B | 3.47B | 3.10B |
| Total Debt | 1.65B | 1.61B | 1.69B | 2.03B | 2.12B |
| Cash & Equivalents | 839.01M | 663.56M | 668.08M | 730.67M | 880.52M |
| Current Assets | 2.00B | 1.96B | 2.15B | 2.39B | 2.11B |
| Current Liabilities | 512.14M | 543.63M | 1.08B | 974.52M | 1.52B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#930 of 1052
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026